Shin Mukai
Dr. Shin Mukai is an ambitious chemical biologist and entrepreneur with a lot of international experience and achievements. He completed his Bachelor's and Master's degrees in Chemistry at Kyoto University in Japan. He obtained a PhD degree in Bio-Organic Chemistry at The University of Western Australia. During his first postdoctoral assignment at the Keio University School of Medicine in Japan, he engaged in biology and immunology research, establishing novel and patented treatments of chronic Graft-Versus-Host Disease. He then moved to Boston for his second postdoctoral position at Brigham and Women’s Hospital/Harvard Medical School and worked on macrophage activation and heterogeneity with a goal of developing new therapies for coronary heart disease. He is passionate about applying his unique blend of expertise in synthetic organic/medicinal chemistry and biology/immunology to cancer research. In 2022, he co-founded the oncology pharmaceutical company New Wind Therapeutics L3C in the US as Chief Executive Officer and Chief Scientific Officer. He is also a member and mentor at Harvard Alumni Entrepreneurs to support the global community of leaders and innovators from all Harvard Schools. His goal is to change the world for the better by beating cancer and becoming a leader who can produce great leaders.